SLC6A2 and Parkinson disease: Recently, the availability of NET in PD patients was studied by PET using the selective NET inhibitor (S,S)‐[11C]‐2‐(α‐(2‐methoxyphenoxy)benzyl)morpholine ([11C]MeNER) (Nahimi, Sommerauer, et al., 2018; Sommerauer et al., 2018).